We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda Pharmaceutical has entered into a collaboration and licensing agreement with US-based gene therapy company StrideBio for the development of in vivo AAV based treatments for neurological disorders.
Multi-target deal will utilize StrideBio’s platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich’s Ataxia